Development of a robust cell-based potency assay for a coxsackievirus A21 oncolytic virotherapy

Development of a robust cell-based potency assay for a coxsackievirus A21 oncolytic virotherapy

Oncolytic viruses (OV) are part of a burgeoning field of investigational oncolytic therapy (OT), in which lytic viruses dissolve advanced tumors productively and specifically. One such OT is a Coxsackievirus A21 (CVA21) based OV that is currently under clinical evaluation. A tissue culture infectiou...

Full description

Bibliographic Details
Main Authors: Venkateswarlu Chamcha, Li He, Jenny Xu, Andrew R. Swartz, Erin Green-Trexler, Kevin Gurney, Tessie McNeely
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Heliyon
Subjects:
Analytical Method Development
Plaque Assay
TCID50 Assay
Method Qualification
Validation
Vaccine development
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024044451

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024044451

Similar Items